Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study Investigating Safety, Tolerability and Effectiveness of Venetoclax Add in Combination With Fludarabine, Cyratabine and Idarubicine in Induction of New Onset Non-M3 Acute Myelid Leukemia

NCT03455504 is registered in ClinicalTrials.gov with Gruppo Italiano Malattie EMatologiche dell'Adulto as lead sponsor.

NCT NCT03455504
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03455504 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study Investigating Safety, Tolerability and Effectiveness of Venetoclax Add in Combination With Fludarabine, Cyratabine and Idarubicine in Induction of New Onset Non-M3 Acute Myelid Leukemia
Lead sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase
Phase 2
Overall status
Completed
Start date
October 26, 2018
Completion date
July 15, 2026
Enrollment
124 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia